Fungos associados as sementes botanicas de mandioquinha-salsa provenientes do Parana.

bitstream/item/109214/1/Fungos-associados-as-sementes-botanicas-de-mandioquinha-salsa-provenientes-do-Parana.pd

Sobrevivência de Colletotrichum gloeosporioides (Penz.) Sacc. em sementes de feijoa (Acca sellowiana Burr.) durante o armazenamento.

bitstream/CENARGEN/23822/1/cot080.pd

Design and baseline characteristics of the finerenone in reducing cardiovascular mortality and morbidity in diabetic kidney disease trial

Background: Among people with diabetes, those with kidney disease have exceptionally high rates of cardiovascular (CV) morbidity and mortality and progression of their underlying kidney disease. Finerenone is a novel, nonsteroidal, selective mineralocorticoid receptor antagonist that has shown to reduce albuminuria in type 2 diabetes (T2D) patients with chronic kidney disease (CKD) while revealing only a low risk of hyperkalemia. However, the effect of finerenone on CV and renal outcomes has not yet been investigated in long-term trials. Patients and Methods: The Finerenone in Reducing CV Mortality and Morbidity in Diabetic Kidney Disease (FIGARO-DKD) trial aims to assess the efficacy and safety of finerenone compared to placebo at reducing clinically important CV and renal outcomes in T2D patients with CKD. FIGARO-DKD is a randomized, double-blind, placebo-controlled, parallel-group, event-driven trial running in 47 countries with an expected duration of approximately 6 years. FIGARO-DKD randomized 7,437 patients with an estimated glomerular filtration rate >= 25 mL/min/1.73 m(2) and albuminuria (urinary albumin-to-creatinine ratio >= 30 to <= 5,000 mg/g). The study has at least 90% power to detect a 20% reduction in the risk of the primary outcome (overall two-sided significance level alpha = 0.05), the composite of time to first occurrence of CV death, nonfatal myocardial infarction, nonfatal stroke, or hospitalization for heart failure. Conclusions: FIGARO-DKD will determine whether an optimally treated cohort of T2D patients with CKD at high risk of CV and renal events will experience cardiorenal benefits with the addition of finerenone to their treatment regimen. Trial Registration: EudraCT number: 2015-000950-39; ClinicalTrials.gov identifier: NCT02545049

Viabilidade e sanidade de sementes de espécies florestais.

Sementes de Aspidosperma sp., Astronium fraxinifolium, A. urundeuva, Didymopanas morototoni, Terminalia fagifolia e Virola sebifera foram avaliadas quanto a viabilidade e sanidade para fins de conservacao "ex situ". as sementes utilizadas foram provenientes de tres reservas geneticas, sendo duas localizadas no Distrito Federal e uma no Estado de Goias. O teste de germinacao foi realizado a temperatura de 20-30oC, utilizando-se como substrato o rolo-de-papel e no teste de tetrazolio utilizou-se uma solucao a 0,075% de sal de tetrazolio. O teste de tetrazolio apresentou valores semelhantes aos de germinacao para as especies Aspidosperma sp., Astronium fraxinifolium e A. arundeuva. As sementes de Didymopanax morototoni, Terminalia fagifolia e Virola sebifera nao germinaram. A incidencia de fungos nessas sementes foi avaliada pelo metodo de papel-de-filtro. Foram detectadas os seguintes fungos potencialmente patogenicos Alternaria sp., Ascochyta sp., Colletotrichum sp.; Fusarium sp.; Helminthosporium sp.; Pestalotia sp.; Phoma sp. e Rhizoctonia sp

Ocorrencia e sobrevivencia de fungos em germoplasma-semente de gergelim (Sesamum indicum L.)

bitstream/CENARGEN/23533/1/bp026.pd